GV-001, An Oral Available Histone Deacetylase 6 Inhibitor for the Treatment of Autosomal Dominant Polycystic Kidney Disease
: 1790 ng·h/mL) in rats, whereas oral administration produced significant therapeutic efficacy in an ADPKD mouse model, along with upregulation of PC1 expression. These results support GV-001 as a promising and selective HDAC6 inhibitor for the treatment of ADPKD.
Authors
- Ji‐Wang Chern (ORCID: https://orcid.org/0000-0002-4310-8834)
- Chao‐Wu Yu (ORCID: https://orcid.org/0000-0002-5176-4225)
- T.Y. Yeh (ORCID: https://orcid.org/0000-0001-7812-5290)
- Pei-Yun Hung
- Po-Jui Lin
- Sian-Siou Wu
Institutions
- National Taiwan University (TW)
- American Association of Colleges of Pharmacy (US)
- G1 Therapeutics (United States) (US)
Publication Details
- Journal
- Journal of Medicinal Chemistry
- Published
- 2026-04-06
- DOI
- https://doi.org/10.1021/acs.jmedchem.5c03139
- Primary Topic
- Genetic and Kidney Cyst Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00